---
title: "Salubris SAL0137 drug clinical trial application accepted"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/261218569.md"
description: "According to the Zhitong Finance APP, Salubris announced that the company has received the acceptance notice issued by the National Medical Products Administration. The clinical trial application for the innovative small molecule drug SAL0137 (project code: SAL0137) developed by the company has been accepted. SAL0137 is an oral small molecule drug developed by the company with independent intellectual property rights. The application submitted by the company is for the clinical trial of SAL0137 for the treatment of elevated lipoprotein (a)"
datetime: "2025-10-15T09:33:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261218569.md)
  - [en](https://longbridge.com/en/news/261218569.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261218569.md)
generator: "portal-rs"
---

# Salubris SAL0137 drug clinical trial application accepted

According to the Zhitong Finance APP, Salubris (002294.SZ) announced that the company has received the acceptance notice issued by the National Medical Products Administration. The clinical trial application for the company's independently developed innovative small molecule drug SAL0137 (project code: SAL0137) has been accepted. SAL0137 is an orally administered small molecule drug developed by the company with independent intellectual property rights. The application submitted by the company is for the clinical trial of SAL0137 for the treatment of elevated lipoprotein(a)

### Related Stocks

- [002294.CN](https://longbridge.com/en/quote/002294.CN.md)

## Related News & Research

- [Vishnusurya Projects and Infra's (NSE:VISHNUINFR) Weak Earnings May Only Reveal A Part Of The Whole Picture](https://longbridge.com/en/news/305559929.md)
- [Pondy Oxides And Chemicals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected](https://longbridge.com/en/news/305560101.md)
- [Alkem Laboratories Limited (NSE:ALKEM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates](https://longbridge.com/en/news/305559747.md)
- [RioCan Real Estate Investment Trust (TSX:REI.UN) Expands Its Buyback Program, Is It Still Undervalued?](https://longbridge.com/en/news/305557624.md)
- [Kava Lend loses roughly $3.8 million to hack, sending KAVA token down nearly 40%](https://longbridge.com/en/news/305556359.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**